Jonne L. Snitselaar

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Differential contributions of human oligosaccharyltransferase complexes OST-A and OST-B to HIV-1 envelope glycoprotein glycosylation.

Differential contributions of human oligosaccharyltransferase complexes OST-A and OST-B to HIV-1 envelope glycoprotein glycosylation.

Journal: Journal of virology

Published: March 04, 2026

Differential contributions of human oligosaccharyltransferase complexes OST-A and OST-B to HIV-1 envelope glycoprotein glycosylation.

Differential contributions of human oligosaccharyltransferase complexes OST-A and OST-B to HIV-1 envelope glycoprotein glycosylation.

Journal: bioRxiv : the preprint server for biology

Published: September 15, 2025

Precise targeting of HIV broadly neutralizing antibody precursors in humans.

Precise targeting of HIV broadly neutralizing antibody precursors in humans.

Journal: Science (New York, N.Y.)

Published: May 15, 2025

Whole-body visualization of SARS-CoV-2 biodistribution in vivo by immunoPET imaging in non-human primates.

Whole-body visualization of SARS-CoV-2 biodistribution in vivo by immunoPET imaging in non-human primates.

Journal: Nature communications

Published: October 10, 2024

Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site.

Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site.

Journal: Science immunology

Published: August 30, 2024

The molecular immune modulator adenosine deaminase-1 enhances HIV specific humoral and cellular responses to a native-like HIV envelope trimer DNA vaccine.

The molecular immune modulator adenosine deaminase-1 enhances HIV specific humoral and cellular responses to a native-like HIV envelope trimer DNA vaccine.

Journal: Research square

Published: May 15, 2024

Mosaic and mixed HIV-1 glycoprotein nanoparticles elicit antibody responses to broadly neutralizing epitopes.

Mosaic and mixed HIV-1 glycoprotein nanoparticles elicit antibody responses to broadly neutralizing epitopes.

Journal: PLoS pathogens

Published: May 07, 2024

Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual.

Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual.

Journal: iScience

Published: February 08, 2023

Broad SARS-CoV-2 Neutralization by Monoclonal and Bispecific Antibodies Derived from a Gamma-infected Individual.

Broad SARS-CoV-2 Neutralization by Monoclonal and Bispecific Antibodies Derived from a Gamma-infected Individual.

Journal: bioRxiv : the preprint server for biology

Published: October 20, 2022

Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions.

Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions.

Journal: Cell reports. Medicine

Published: September 15, 2022

Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses.

Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses.

Journal: iScience

Published: June 24, 2022

A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike.

A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike.

Journal: Nature communications

Published: November 30, 2021

Showing 1-12 of 20

Last Updated: 09/26/2026